Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR7 | P34969 | 3/20 | 0.47 |
| ▸ | LTA4H | P09960 | 2/20 | 0.47 |
| ▸ | HTR1B | P28222 | 1/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.44 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | DRD2 | P14416 | 1/20 | 0.42 |
| ▸ | DRD1 | P21728 | 1/20 | 0.42 |
| ▸ | DRD4 | P21917 | 1/20 | 0.42 |
| ▸ | DRD5 | P21918 | 1/20 | 0.42 |
| ▸ | CHRNB2 | P17787 | 2/20 | 0.41 |
| ▸ | CHRNA4 | P43681 | 2/20 | 0.41 |
| ▸ | POLB | P06746 | 1/20 | 0.41 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.41 |
| ▸ | LMNA | P02545 | 1/20 | 0.41 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.41 |
| ▸ | CHRM2 | P08172 | 1/20 | 0.41 |
| ▸ | CHRM4 | P08173 | 1/20 | 0.41 |
| ▸ | CHRM5 | P08912 | 1/20 | 0.41 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3125003 | 0.91 | LSS (0.49) | HTR1BALDH1A1KDM4ESMN1; SMN2HRH3 | |
| SCHEMBL930341 | 0.82 | CYP2D6 (0.47) | LTA4HALDH1A1KDM4EDRD2DRD1 | |
| SCHEMBL6238419 | 0.82 | JAK2 (0.33) | ALDH1A1KDM4ESMN1; SMN2LMNAHTT | |
| SCHEMBL6553844 | 0.81 | ESR1 (0.33) | HTR7LTA4HALDH1A1TSHR | |
| SCHEMBL6633045 | 0.81 | LTA4H (0.49) | LTA4HCHRNB2CHRNA4CHRM2CHRM1 | |
| SCHEMBL126227 | 0.79 | ALDH1A1 (0.34) | LTA4HALDH1A1KDM4ESMN1; SMN2POLB | |
| SCHEMBL6506292 | 0.78 | KMT2A (0.46) | ALDH1A1KDM4ESMN1; SMN2DRD1LMNA | |
| SCHEMBL7631848 | 0.78 | SIGMAR1 (0.41) | HTR7HTR1BCHRM2 | |
| SCHEMBL3122100 | 0.77 | ALDH1A1 (0.46) | LTA4HALDH1A1KDM4EDRD1CYP1A2 | |
| SCHEMBL3130677 | 0.77 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 99 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-107879975-B | Histone deacetylase inhibitor and application thereof | 中国科学院上海药物研究所 | 2022-07-26 | — | — | CN | claimed |
| EP-2951179-B1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2020-03-11 | — | — | EP | claimed |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | FORMA TM, LLC (US) | 2019-04-30 | — | — | US | claimed |
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | FORMA TM, LLC (US) | 2017-12-28 | — | — | US | claimed |
| US-9708321-B2 | Spiro-quinazolinone derivatives and their use as positive allosteric modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2017-07-18 | — | — | US | claimed |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | MERCK PATENT GMBH (DE) | 2015-12-17 | — | — | US | claimed |
| EP-2951179-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | Merck Patent GmbH (DE) | 2015-12-09 | — | — | EP | claimed |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | VALO EARLY DISCOVERY, INC. | 2014-10-02 | — | — | US | claimed |
| WO-2014117920-A1 | SPIRO-QUINAZOLINONE DERIVATIVES USEFUL FOR THE TREATMENT OF NEUROLOGICAL DISEASES AND CONDITIONS | MERCK PATENT GMBH (DE) | 2014-08-07 | — | — | WO | claimed |
| US-8012956-B2 | Tropane compounds | EXELIXIS, INC. (US) | 2011-09-06 | — | — | US | claimed |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | SMITHKLINE BEECHAM P.L.C. (GB) | 2004-01-29 | — | — | US | claimed |
| EP-0815859-B1 | INTIMAL THICKENING INHIBITORS | TAIHO PHARMACEUTICAL CO LTD (JP) | 2003-06-18 | — | — | EP | claimed |
| EP-1319001-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM PLC (GB) | 2003-06-18 | — | — | EP | claimed |
| WO-2002024694-A1 | PYRAZOLOPYRIDINES AND PYRAZOLOPYRIDAZINES AS ANTIDIABETICS | SMITHKLINE BEECHAM, P.L.C. (GB) | 2002-03-28 | — | — | WO | claimed |
| US-5977130-A | CARDIOVASCULAR DISORDERS | TAIHO PHARMEUTICAL CO., LTD. (JP) | 1999-11-02 | — | — | US | claimed |
| EP-0710646-B1 | 1,5-Disubstituted 7a-methylperhydroinden-3a-ol derivatives, active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them | SIGMA TAU IND FARMACEUTI (IT) | 1998-12-16 | — | — | EP | claimed |
| EP-0815859-A1 | INTIMAL THICKENING INHIBITORS | TAIHO PHARMACEUTICAL COMPANY LIMITED (JP) | 1998-01-07 | — | — | EP | claimed |
| EP-0710646-A1 | 1,5-disubstituted 7a-methylperhydroinden-3a-ol derivatives, active on the cardiovascular system, processes for their preparation and pharmaceutical compositions containing them | Sigma-Tau Industrie Farmaceutiche Riunite S.p.A. (IT) | 1996-05-08 | — | — | EP | claimed |
| EP-0168288-B1 | Aminomethyl-6-furo-[3,4-c]pyridine derivatives, process for their preparation and pharmaceutical compositions containing them | SOCIETE DE CONSEILS DE RECHERCHES ET D'APPLICATIONS SCIENTIFIQUES (S.C.R.A.S.) (FR) | 1990-04-25 | — | — | EP | claimed |
| US-3978055-A | SEDATIVE, ANTIINFLAMMATORY, VASODILATION, BRONCHODILATION | DELALANDE S.A. (FR) | 1976-08-31 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170368039-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HTR7 3334/4885LTA4H 2761/4885HTR1B 1431/4885 |
| US-20150361079-A1 | Spiro-Quinazolinone Derivatives and their Use as Positive Allosteric Modulators of mGluR4 | GRM4, GRIA4, GRIK4 | HTR7 243/4885LTA4H 3546/4885HTR1B 313/4885 |
| US-20140294805-A1 | NOVEL COMPOUNDS AND COMPOSITIONS FOR THE INHIBITION OF NAMPT | NAMPT, NNMT, NQO1 | HTR7 3334/4885LTA4H 2761/4885HTR1B 1431/4885 |
| US-10272072-B2 | Compounds and compositions for the inhibition of NAMPT | NAMPT, NNMT, NQO1 | HTR7 3090/4885LTA4H 2984/4885HTR1B 1332/4885 |
| US-20040019052-A1 | Pyrazolopyridines and pyrazolopyridazines as antidabetics | PDXK, GCK, IAPP | HTR7 1707/4885LTA4H 2800/4885HTR1B 985/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.